GlassScriptPhysician profile
Thomas V Ayoub
NPI 1700990652
$1,544.00
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,172 · 2020: $236 · 2021: $135.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $277.87 | 2019 | |
| Abbvie INC. | $225.02 | 2019-2020 | |
| Astellas Pharma US INC | $132.61 | 2019 | |
| Amgen INC. | $128.84 | 2019-2021 | |
| Medtronic Vascular, INC. | $127.62 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $112.93 | 2019-2020 | |
| Coopersurgical, INC. | $100.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $77.08 | 2019-2021 | |
| Millicent US INC | $66.12 | 2019 | |
| Lupin INC. | $60.04 | 2019 | |
| Pfizer INC. | $57.53 | 2019 | |
| Merck Sharp & Dohme LLC | $45.66 | 2019-2020 | |
| Covidien LP | $28.08 | 2019 | |
| Vertical Pharmaceuticals, LLC | $24.46 | 2019 | |
| Duchesnay USA Incorporated | $18.73 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clovis Oncology, INC. | $16.33 | 2019 | |
| Mission Pharmacal Company | $16.16 | 2019 | |
| Amag Pharmaceuticals, INC. | $15.09 | 2019 | |
| Allergan, INC. | $13.83 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Ayoub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.